Padraig Warde
YOU?
Author Swipe
View article: Long-term Relapse and Survival in Clinical Stage I Testicular Teratoma
Long-term Relapse and Survival in Clinical Stage I Testicular Teratoma Open
We compared survival rates after testicle removal in clinical stage I testicular cancer for two different tumor types. We found that cancer-specific and overall survival rates were similar for pure teratoma tumors and nonseminoma tumors, a…
View article: Primary retroperitoneal lymph node dissection for metastatic non‐seminomatous germ cell tumours: outcomes and adjuvant chemotherapy
Primary retroperitoneal lymph node dissection for metastatic non‐seminomatous germ cell tumours: outcomes and adjuvant chemotherapy Open
Objectives To compare the outcomes and treatment burden of primary retroperitoneal lymph node dissection (pRPLND) alone versus pRPLND + adjuvant chemotherapy (AC) in patients with pathological stage II (PSII) non‐seminomatous germ cell tum…
View article: Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-Linac
Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-Linac Open
Intrafraction motion observed during prostate SBRT treatment on the MR-Linac have dosimetric impacts on both the target and organs at risk. Post-treatment computation using DDOTD may inform adaptation beyond anatomic changes in subsequent …
View article: Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists
Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists Open
Introduction: Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent oncological efficacy and tolerability. We investigated the proportion of physicians who predom…
View article: Delivery of Cancer Care in Ontario, Canada, During the First Year of the COVID-19 Pandemic
Delivery of Cancer Care in Ontario, Canada, During the First Year of the COVID-19 Pandemic Open
In this population-based cohort study in Ontario, Canada, large reductions in cancer service volumes were observed. While most services recovered to prepandemic levels at the end of the first pandemic year, a substantial care deficit likel…
View article: Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy
Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy Open
Introduction: To compare the dosimetry of prostate stereotactic radiotherapy (SBRT) delivered by adaptive intensity modulated radiotherapy (A-IMRT) and 3 degree of freedom volumetric modulated arc therapy (3DOF-VMAT). Methods & Materials: …
View article: Economic Evaluation of a Geriatric Oncology Clinic
Economic Evaluation of a Geriatric Oncology Clinic Open
Geriatric assessment (GA) is supported by recent trials and guidelines yet rarely implemented due to a lack of resources. We performed an economic evaluation of a geriatric oncology clinic. Pre-GA proposed treatments and post-GA actual tre…
View article: Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model
Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model Open
Introduction: Radical cystectomy (RC) is the historic gold standard treatment for muscle-invasive bladder cancer (MIBC), but trimodal therapy (TMT) has emerged as a valid therapeutic option for selected patients. Given that prospective cli…
View article: Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223 Open
Background In men with metastatic castration‐resistant prostate cancer (mCRPC) with primarily bone metastases, radium‐223 ( 223 Ra) improves overall survival (OS). However, the selection of 223 Ra is not guided by specific validated clinic…
View article: Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer Open
These findings suggest that most older men do not experience significant cognitive decline in attention, executive function, and global cognition while undergoing treatment for advanced prostate cancer regardless of the treatment used.
View article: Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant prostate cancer
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant prostate cancer Open
BACKGROUND Because multiple treatments are available for metastatic castrate‐resistant prostate cancer (mCRPC) and most patients are elderly, the prediction of toxicity risk is important. The Cancer and Aging Research Group (CARG) tool pre…
View article: The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer Open
We investigated the prognostic utility of pre-chemotherapy neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors (GCTs) undergoing first-line chemotherapy. We utilized two institutional databases to analyze the …
View article: Clinical dilemmas in local and regional testis cancer
Clinical dilemmas in local and regional testis cancer Open
At the Canadian Testis Cancer Workshop, the multidisciplinary management of testis cancer care was discussed. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, radiologists, physician’s assistants, …
View article: Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada
Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada Open
Introduction: The biennial meeting of the Genitourinary Radiation Oncologists of Canada (GUROC) took place 22-23 November 2019. A consensus-building session was held during the meeting addressing topics of emerging interest or controversy …
View article: Discrepancy in pathology reports upon second review of radical orchiectomy specimens for testicular germ cell tumors
Discrepancy in pathology reports upon second review of radical orchiectomy specimens for testicular germ cell tumors Open
Introduction: We sought to evaluate the discrepancies between primary pathology report and second pathology review of radical orchiectomy (RO) specimens.
Methods: A retrospective review was performed of RO specimens from the Ontario Cance…
View article: Controversies in the management of clinical stage 1 testis cancer
Controversies in the management of clinical stage 1 testis cancer Open
In November 2018, The Canadian Testis Cancer Workshop was convened. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, radiologists, physician’s assistants, residents and fellows, nurses, patients an…
View article: [ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
[ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial Open
Introduction The oligometastatic (OM) disease hypothesis of an intermediate metastatic state with limited distant disease deposits amenable for curative therapies remains debatable. Over a third of prostate cancer (PCa) patients treated wi…